Marius IliÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3360010/publications.pdf

Version: 2024-02-01

176 papers	8,398 citations	44042 48 h-index	56687 83 g-index

226 all docs	226 docs citations	226 times ranked	12414 citing authors

#	Article	IF	Citations
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. Journal of Clinical Pathology, 2023, 76, 47-52.	1.0	9
2	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	1.0	6
3	Fusionâ€positive nonâ€small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. Genes Chromosomes and Cancer, 2022, 61, 244-260.	1.5	32
4	Lâ€™Ã©valuation des mutations de lâ€™EGFR des carcinomes non Ã petites cellules de stade prÃ©coce. Revue Francophone Des Laboratoires, 2022, 2022, 49-55.	0.0	0
5	Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer. Lung Cancer, 2022, 166, 1-8.	0.9	10
6	Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner. Cancers, 2022, 14, 1628.	1.7	9
7	Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes. Diagnostics, 2022, 12, 751.	1.3	3
8	Deep Learning Facilitates Distinguishing Histologic Subtypes of Pulmonary Neuroendocrine Tumors on Digital Whole-Slide Images. Cancers, 2022, 14, 1740.	1.7	4
9	Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). Cancers, 2022, 14, 2258.	1.7	17
10	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. European Journal of Cancer, 2022, 169, 106-122.	1.3	12
11	Abstract 461: Mixed supervision to improve the classification and localization: Coherence of tumors in histological slides. Cancer Research, 2022, 82, 461-461.	0.4	0
12	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2816.	1.7	3
13	Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. European Journal of Cancer, 2021, 143, 158-167.	1.3	10
14	Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 5-19.	1.4	44
15	Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. ESMO Open, 2021, 6, 100024.	2.0	13
16	Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System. Frontiers in Pharmacology, 2021, 12, 657743.	1.6	13
17	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 807-816.	0.5	11
18	Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay. Annals of Translational Medicine, 2021, 9, 922-922.	0.7	8

#	Article	IF	Citations
19	A rapid near-patient RT-PCR test for suspected COVID-19: a study of the diagnostic accuracy. Annals of Translational Medicine, 2021, 9, 921-921.	0.7	11
20	Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients. Cells, 2021, 10, 1920.	1.8	15
21	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	1.7	7
22	Salivary detection of COVID-19: clinical performance of oral sponge sampling for SARS-CoV-2 testing. ERJ Open Research, 2021, 7, 00396-2021.	1.1	4
23	Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. Oncolmmunology, 2021, 10, 1901446.	2.1	2
24	Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test. Microbiology Spectrum, 2021, 9, e0099621.	1.2	2
25	Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France). Frontiers in Medicine, 2021, 8, 730577.	1.2	5
26	Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit. Journal of the American Academy of Dermatology, 2020, 82, 731-733.	0.6	5
27	Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Nonâ€“Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France). Clinical Lung Cancer, 2020, 21, 56-65.e8.	1.1	23
28	â€œInterchangeabilityâ€•of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	2.9	135
29	Association of combined <scp>PD</scp>â€L1 expression and tumourâ€infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 984-994.	1.3	31
30	18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1158-1167.	3.3	72
31	Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation. JCO Precision Oncology, 2020, 4, 1239-1245.	1.5	13
32	P2RX7B is a new theranostic marker for lung adenocarcinoma patients. Theranostics, 2020, 10, 10849-10860.	4.6	25
33	Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability. Journal of Thoracic Oncology, 2020, 15, 1535-1540.	0.5	13
34	Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. , 2020, 8, e000645.		54
35	Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 709-716.	5.2	83
36	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin Du Cancer, 2020, 107, 946-958.	0.6	15

#	Article	IF	Citations
37	Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France). Lung Cancer, 2020, 145, 58-62.	0.9	12
38	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. Journal of Thoracic Oncology, 2020, 15, 1037-1053.	0.5	40
39	Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution. Journal of Translational Medicine, 2020, 18, 87.	1.8	8
40	Intelligence artificielle et pathologistes, est-ce bien raisonnable ?. Revue Francophone Des Laboratoires, 2020, 2020, 34-39.	0.0	0
41	Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France). Cancers, 2020, 12, 955.	1.7	16
42	Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France). Biopreservation and Biobanking, 2020, 18, 517-524.	0.5	11
43	The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene, 2019, 38, 7146-7165.	2.6	75
44	Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review. Therapeutic Advances in Urology, 2019, 11, 175628721987557.	0.9	3
45	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 2019, 11, 1271.	1.7	27
46	Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients. Journal of Thoracic Oncology, 2019, 14, 1204-1212.	0.5	35
47	Circulating Tumor Cell Detection in Lung Cancer: But to What End?. Cancers, 2019, 11, 262.	1.7	19
48	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancerâ€"Just About Ready for Prime-Time?. Cancers, 2019, 11, 283.	1.7	86
49	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	5.8	125
50	The Long Noncoding RNA DNM3OS Is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF-Î² and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 184-198.	2.5	78
51	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. Journal of Thoracic Disease, 2019, 11, S89-S101.	0.6	52
52	Resistances to EGFR tyrosine kinase inhibitors in lung cancerâ€"how to routinely track them in a molecular pathology laboratory?. Journal of Thoracic Disease, 2019, 11, S65-S70.	0.6	11
53	The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. Cancers, 2019, 11, 250.	1.7	2
54	Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. Journal of Thoracic Disease, 2019, 11, S71-S80.	0.6	71

#	Article	IF	Citations
55	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine, 2019, 48, 191-202.	2.7	55
56	Pulmonary hypertension due to pulmonary artery obstructions by malignant tumoral cells. Respiratory Medicine and Research, 2019, 76, 10-12.	0.4	1
57	A case report of exogenous lipoid pneumonia associated with avocado/soybean unsaponifiables. BMC Pulmonary Medicine, 2019, 19, 234.	0.8	4
58	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
59	Liquid Biopsy and Genomic Assessment for Lung Cancer. , 2019, , 165-180.		0
60	Use of the 22C3 antiâ€“programmed deathâ€ligand 1 antibody to determine programmed deathâ€ligand 1 expression in cytology samples obtained from nonâ€“small cell lung cancer patients. Cancer Cytopathology, 2018, 126, 264-274.	1.4	74
61	Use of circulating tumor cells in prospective clinical trials for NSCLC patients â€“ standardization of the pre-analytical conditions. Clinical Chemistry and Laboratory Medicine, 2018, 56, 980-989.	1.4	24
62	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology, 2018, 29, 193-199.	0.6	162
63	Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma. Oncotarget, 2018, 9, 20058-20074.	0.8	20
64	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Current Molecular Medicine, 2018, 17, 527-540.	0.6	20
65	Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget, 2018, 9, 36238-36249.	0.8	28
66	Dermoscopy of eccrine angiomatous hamartoma: The spitzoid pattern. JAAD Case Reports, 2018, 4, 835-836.	0.4	9
67	ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the questionâ€”to treat or not to treat?. ESMO Open, 2018, 3, e000419.	2.0	23
68	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. Journal of Visualized Experiments, 2018, , .	0.2	1
69	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. British Journal of Cancer, 2018, 119, 950-960.	2.9	133
70	Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. Cancers, 2018, 10, 326.	1.7	23
71	Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer, 2018, 121, 70-75.	0.9	51
72	Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. Cancers, 2018, 10, 88.	1.7	13

#	Article	IF	Citations
73	Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. Cancers, 2018, 10, 108.	1.7	120
74	Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers, 2018, 10, 195.	1.7	6
75	Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?. Cancers, 2018, 10, 220.	1.7	13
76	Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?. Cancers, 2018, 10, 70.	1.7	21
77	Matrix Stiffening and EGFR Cooperate to Promote the Collective Invasion of Cancer Cells. Cancer Research, 2018, 78, 5229-5242.	0.4	72
78	Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer. Lung Cancer, 2018, 124, 90-94.	0.9	31
79	Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma. Translational Lung Cancer Research, 2018, 7, 614-615.	1.3	1
80	Rapid decay of engulfed extracellular miRNA by XRN1 exonuclease promotes transient epithelial-mesenchymal transition. Nucleic Acids Research, 2017, 45, gkw1284.	6.5	39
81	Fibronectin-guided migration of carcinoma collectives. Nature Communications, 2017, 8, 14105.	5.8	143
82	Metformin monotherapy in melanoma: a pilot, openâ€label, prospective, and multicentric study indicates no benefit. Pigment Cell and Melanoma Research, 2017, 30, 378-380.	1.5	23
83	NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?. Expert Review of Anticancer Therapy, 2017, 17, 681-685.	1.1	8
84	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. OncoImmunology, 2017, 6, e1339856.	2.1	8
85	Les biobanques : quels enjeux en 2017 ?. Revue Francophone Des Laboratoires, 2017, 2017, 25-29.	0.0	5
86	Lâ€™accrÃ©ditation des laboratoires dâ€™ACP : pourquoi est-ce incontournable ?. Revue Francophone Des Laboratoires, 2017, 2017, 31-37.	0.0	1
87	The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases. Expert Review of Anticancer Therapy, 2017, 17, 1087-1092.	1.1	16
88	Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open, 2017, 7, e018884.	0.8	26
89	Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget, 2017, 8, 103055-103062.	0.8	47
90	Use of the 22C3 antiâ€“PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE, 2017, 12, e0183023.	1.1	73

#	Article	IF	Citations
91	Atezolizumab in advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3603-3606.	0.6	7
92	Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Oncotarget, 2017, 8, 26112-26121.	0.8	45
93	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: whatâ€™s next?. Journal of Thoracic Disease, 2017, 9, E519-E521.	0.6	3
94	Reproducibility of PD-L1 assessment in non-small cell lung cancerâ€"know your limits but never stop trying to exceed them. Translational Lung Cancer Research, 2017, 6, S51-S54.	1.3	12
95	MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 57174-57186.	0.8	28
96	Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational Lung Cancer Research, 2016, 5, 420-423.	1.3	162
97	Rebuttal from Dr. Hofman and Dr. IliÃ©. Translational Lung Cancer Research, 2016, 5, 428-429.	1.3	3
98	p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis. Genes and Development, 2016, 30, 2623-2636.	2.7	43
99	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. Cancer Cell, 2016, 29, 805-819.	7.7	201
100	High expression of <scp>TRF</scp>2, <scp>SOX</scp>10, and <scp>CD</scp>10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. Cancer Medicine, 2016, 5, 1022-1030.	1.3	40
101	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology, 2016, 29, 1552-1564.	2.9	25
102	Liquid biopsy testing in routine clinical management of advanced non-small cell lung cancer: clinical validation in a single biopathology laboratory. Annals of Oncology, 2016, 27, vi18.	0.6	0
103	Detection and characterization of circulating tumor cells in lung cancer: Why and how?. Cancer Cytopathology, 2016, 124, 380-387.	1.4	22
104	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 511-525.	1.4	212
105	Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology, 2016, 27, 147-153.	0.6	466
106	MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget, 2016, 7, 30461-30478.	0.8	44
107	Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients. Translational Cancer Research, 2016, 5, 203-205.	0.4	1
108	Setting up a wide panel of patientâ€derived tumor xenografts of nonâ€"small cell lung cancer by improving the preanalytical steps. Cancer Medicine, 2015, 4, 201-211.	1.3	71

#	Article	IF	Citations
109	KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives. Current Molecular Medicine, 2015, 15, 418-432.	0.6	40
110	Why and how immunohistochemistry should now be used to screen for the <scp>BRAFV</scp>600E status in metastatic melanoma? The experience of a single institution (<scp>LCEP</scp>, Nice, France). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2436-2443.	1.3	16
111	IntÃ©rÃªt de lâ€™immunohistochimie Ã visÃ©e thÃ©ranostique dans les carcinomes bronchiques non Ã petites cellules : applications et limites actuelles. Revue Francophone Des Laboratoires, 2015, 2015, 37-47.	0.0	0
112	Reply to the letter to the editor â€˜ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancerâ€™ by Uguen et al.. Annals of Oncology, 2015, 26, 1802.	0.6	9
113	Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. Journal of the American Academy of Dermatology, 2015, 72, 786-793.	0.6	37
114	Local Mitochondrial-Endolysosomal Microfusion Cleaves Voltage-Dependent Anion Channel 1 To Promote Survival in Hypoxia. Molecular and Cellular Biology, 2015, 35, 1491-1505.	1.1	40
115	Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer. Cancer Research, 2015, 75, 835-845.	0.4	96
116	French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. European Respiratory Journal, 2015, 46, 207-218.	3.1	54
117	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.	1.3	10
118	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK â€˜borderlineâ€™-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Annals of Oncology, 2015, 26, 238-244.	0.6	99
119	Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene, 2015, 34, 3640-3650.	2.6	168
120	â€œSentinelâ€•Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e111597.	1.1	339
121	A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib. Journal of Investigative Dermatology, 2014, 134, 1473-1476.	0.3	4
122	Detection ofBRAFp.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	1.2	57
123	Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. British Journal of Cancer, 2014, 110, 1236-1243.	2.9	55
124	BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Pathology, 2014, 46, 311-315.	0.3	10
125	Macular eruption revealing hypomelanotic cutaneous melanoma metastases: Diagnostic role of dermoscopy. Journal of the American Academy of Dermatology, 2014, 70, e7-e9.	0.6	2
126	Les mÃ©thodes de sÃ©quenÃ§age de Â« nouvelle gÃ©nÃ©ration Â» (NGS) et le cancer broncho-pulmonaire: principales technologies, applications et limites actuelles en pathologie. Revue Francophone Des Laboratoires, 2014, 2014, 51-58.	0.0	0

#	Article	IF	Citations
127	Diagnostic Value of Immunohistochemistry for the Detection of the BRAF^{V600E} Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays. Thyroid, 2014, 24, 858-866.	2.4	57
128	Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls. Current Molecular Medicine, 2014, 14, 440-456.	0.6	58
129	In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF V600E mutation status and together with hypoxia-related proteins predicts aggressive behavior. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 437-444.	1.4	20
130	Autophagy Plays a Critical Role in the Degradation of Active RHOA, the Control of Cell Cytokinesis, and Genomic Stability. Cancer Research, 2013, 73, 4311-4322.	0.4	88
131	Measuring the Contribution of Tumor Biobanks to Research in Oncology: Surrogate Indicators and Bibliographic Output. Biopreservation and Biobanking, 2013, 11, 235-244.	0.5	29
132	Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. Annals of Oncology, 2013, 24, 742-748.	0.6	103
133	Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients. Lung Cancer, 2013, 82, 16-23.	0.9	20
134	Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2745-2749.	0.8	53
135	Usefulness of Ancillary Methods for Diagnosis, Prognosis and Targeted Therapy in Thyroid Pathology. Current Medicinal Chemistry, 2013, 20, 639-654.	1.2	4
136	Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. Journal of Investigative Dermatology, 2013, 133, 1378-1381.	0.3	39
137	The Potential Value of Immunohistochemistry as a Screening Tool for Oncogenic Targets of Personalized Lung Cancer Therapy. The Journal of Oncopathology, 2013, 1, 82-92.	0.1	8
138	Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC. PLoS ONE, 2013, 8, e54596.	1.1	146
139	Usefulness of Molecular Biology in Follicular-Derived Thyroid Tumors: From Translational Research to Clinical Practice. , 2013, , 391-428.		0
140	Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?. Current Medicinal Chemistry, 2012, 19, 2638-2651.	1.2	28
141	Expression of a Truncated Active Form of VDAC1 in Lung Cancer Associates with Hypoxic Cell Survival and Correlates with Progression to Chemotherapy Resistance. Cancer Research, 2012, 72, 2140-2150.	0.4	64
142	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Annals of Oncology, 2012, 23, 2907-2913.	0.6	142
143	Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Annals of Oncology, 2012, 23, 1738-1743.	0.6	55
144	Expression de lâ€™anhydrase carboniqueÂIX et fixation du 18F-FDG dans les cancers pulmonaires non Ã petites cellules. Medecine Nucleaire, 2012, 36, 495-503.	0.2	0

#	Article	IF	Citations
145	Morphological analysis of circulating tumour cells in patients undergoing surgery for nonâ€small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology, 2012, 23, 30-38.	0.4	117
146	Predictive clinical outcome of the intratumoral CD66bâ€positive neutrophilâ€toâ€CD8â€positive Tâ€cell ratio in patients with resectable nonsmall cell lung cancer. Cancer, 2012, 118, 1726-1737.	2.0	146
147	Cadmium-Induced Autophagy in Rat Kidney: An Early Biomarker of Subtoxic Exposure. Toxicological Sciences, 2011, 121, 31-42.	1.4	135
148	Overexpression of carbonic anhydrase XII in tissues from resectable nonâ€small cell lung cancers is a biomarker of good prognosis. International Journal of Cancer, 2011, 128, 1614-1623.	2.3	84
149	Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for nonâ€smallâ€cell lung carcinoma: comparison of the efficacy of the CellSearch Assayâ„¢ and the isolation by size of epithelial tumor cell method. International Journal of Cancer, 2011, 129, 1651-1660.	2.3	272
150	Setting up a Prospective Thyroid Biobank for Translational Research: Practical Approach of a Single Institution (2004â€“2009, Pasteur Hospital, Nice, France). Biopreservation and Biobanking, 2011, 9, 9-19.	0.5	9
151	MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocrine-Related Cancer, 2011, 18, 711-719.	1.6	77
152	Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker. Clinical Cancer Research, 2011, 17, 827-835.	3.2	281
153	Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method. American Journal of Clinical Pathology, 2011, 135, 146-156.	0.4	122
154	Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?. Endocrine-Related Cancer, 2011, 18, 579-594.	1.6	31
155	Polypoid intranasal mass caused by Rosaiâ€“Dorfman disease: a diagnostic pitfall. Journal of Laryngology and Otology, 2010, 124, 345-348.	0.4	5
156	Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 483-495.	1.4	46
157	Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathology Research and Practice, 2010, 206, 66-72.	1.0	19
158	Disseminated infection caused by Sparganum proliferum in an AIDS patient. Histopathology, 2010, 56, 824-828.	1.6	17
159	Usefulness of oral cytopathology in the diagnosis of infectious diseases. Cytopathology, 2010, 21, 285-299.	0.4	19
160	High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. British Journal of Cancer, 2010, 102, 1627-1635.	2.9	156
161	Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications. Current Medicinal Chemistry, 2010, 17, 1839-1850.	1.2	39
162	The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.. Current Medicinal Chemistry, 2010, 17, 3449-3461.	1.2	49

#	Article	IF	Citations
163	MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets. Current Medicinal Chemistry, 2009, 16, 1047-1061.	1.2	89
164	Assessment of Morphology, Antigenicity, and Nucleic Acid Integrity for Diagnostic Thyroid Pathology Using Formalin Substitute Fixatives. Thyroid, 2009, 19, 1239-1248.	2.4	45
165	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for antiâ€EGFR treatment of a rare lung malignancy. International Journal of Cancer, 2009, 125, 2479-2482.	2.3	103
166	LANA-1, Bcl-2, Mcl-1 and HIF-1Î± protein expression in HIV-associated Kaposi sarcoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 159-170.	1.4	21
167	Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 21-33.	1.4	46
168	Pericardial effusion as primary manifestation of metastatic cutaneous adenoid cystic carcinoma: Diagnostic cytopathology from an exfoliative sample. Diagnostic Cytopathology, 2008, 36, 351-354.	0.5	13
169	Involvement of mast cells in gastritis caused by Helicobacter pylori: a potential role in epithelial cell apoptosis. Journal of Clinical Pathology, 2007, 60, 600-607.	1.0	20
170	Sarcoid-like lesions associated with the immune restoration inflammatory syndrome in AIDS: absence of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 689-696.	1.4	10
171	The value of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Pathology, 2004, 36, 77-81.	0.3	27
172	Immunostaining of Visceral Leishmaniasis Caused byLeishmania infantumUsing Monoclonal Antibody (19â€“11) to theLeishmaniaHomologue of Receptors for Activated C-Kinase. American Journal of Clinical Pathology, 2003, 120, 567-574.	0.4	20
173	Usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management. Pathology, 2003, 35, 212-216.	0.3	42
174	Immunostaining of Visceral Leishmaniasis Caused by Leishmania infantum Using Monoclonal Antibody (19-11) to the Leishmania Homologue of Receptors for Activated C-Kinase. American Journal of Clinical Pathology, 2003, 120, 567-574.	0.4	7
175	Longterm Survival in Acute Rhinocerebral Mucormycosis with Giant Cell Arteritis and Foreign Body Granulomas. Pathology Research and Practice, 2001, 197, 199-203.	1.0	13
176	The histological spectrum of visceral leishmaniasis caused by Leishmania infantum MON-1 in acquired immune deficiency syndrome. Human Pathology, 2000, 31, 75-84.	1.1	46